These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37258788)

  • 21. A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice.
    Soncin S; Lo Cicero V; Astori G; Soldati G; Gola M; Sürder D; Moccetti T
    J Transl Med; 2009 Sep; 7():78. PubMed ID: 19737416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe.
    Ten Ham RMT; Hoekman J; Hövels AM; Broekmans AW; Leufkens HGM; Klungel OH
    Mol Ther Methods Clin Dev; 2018 Dec; 11():121-130. PubMed ID: 30456217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
    Seimetz D; Heller K; Richter J
    Cell Med; 2019; 11():2155179018822781. PubMed ID: 32634192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What will (and should) be improved in CAR immunotherapy?
    González-Navarro EA; Español M; Egri N; Castellà M; Calderón H; España C; Guijarro C; Heredia L; Pascal M; Juan Otero M
    Int Rev Cell Mol Biol; 2022; 370():149-161. PubMed ID: 35798504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites.
    Pillai M; Davies MM; Thistlethwaite FC
    Ther Adv Vaccines Immunother; 2020; 8():2515135520944355. PubMed ID: 33015538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy.
    de Wolf C; van de Bovenkamp M; Hoefnagel M
    Cytotherapy; 2017 Jul; 19(7):784-797. PubMed ID: 28457740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value and affordability of CAR T-cell therapy in the United States.
    Fiorenza S; Ritchie DS; Ramsey SD; Turtle CJ; Roth JA
    Bone Marrow Transplant; 2020 Sep; 55(9):1706-1715. PubMed ID: 32474570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On CAR-Ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies.
    Arnaudo L
    J Law Biosci; 2022; 9(2):lsac027. PubMed ID: 36168389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full GMP-compliant validation of bone marrow-derived human CD133(+) cells as advanced therapy medicinal product for refractory ischemic cardiomyopathy.
    Belotti D; Gaipa G; Bassetti B; Cabiati B; Spaltro G; Biagi E; Parma M; Biondi A; Cavallotti L; Gambini E; Pompilio G
    Biomed Res Int; 2015; 2015():473159. PubMed ID: 26495296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
    Liu Y; Chen X; Han W; Zhang Y
    Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
    Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
    Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy.
    DE Wolf C; VAN DE Bovenkamp M; Hoefnagel M
    Cytotherapy; 2018 Nov; 20(11):1289-1308. PubMed ID: 30327247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remestemcel-L for acute graft-versus-host disease therapy.
    Chen GL; Paplham P; McCarthy PL
    Expert Opin Biol Ther; 2014 Feb; 14(2):261-9. PubMed ID: 24350681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
    Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
    J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy.
    de Wolf C; van de Bovenkamp M; Hoefnagel M
    Cytotherapy; 2018 May; 20(5):601-622. PubMed ID: 29598903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union.
    Pellegrini G; Ardigò D; Milazzo G; Iotti G; Guatelli P; Pelosi D; De Luca M
    Stem Cells Transl Med; 2018 Jan; 7(1):146-154. PubMed ID: 29280318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework.
    López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis.
    Van Wilder P
    Front Pharmacol; 2012; 3():12. PubMed ID: 22347860
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.